Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on 4D Molecular Therapeutics (NASDAQ:FDMT).
September 09, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on 4D Molecular Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100